Ketamine Infusion in Neurologic Deficit

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (107 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-11-15. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: brainsmallheartctventricular
  Phrases that lowered it: femalephysicaldrughealthmale
• Sponsor's past termination rate: 4% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 48 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Drug's FAERS reports with a death: 17.1% (lowers risk) · Drug's FDA history
• Blinding: triple (raises risk) · Design
• Design: parallel (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, neurology: Yes (raises risk) · Disease area
• Drug's FAERS reports marked serious: 94.1% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Sponsor's past trials: 75 (lowers risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Maximum age: 80 (lowers risk) · Who can join
• Phase: 2/3 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Clinical Research Study With Clazosentan to Evaluate Its Effects on Preventing Complications Due to the Narrowing of the Blood Vessels (Vasospasm) in the Brain, Caused by Bleeding Onto the Surface of the Brain NCT03585270 · started 2019 · scored riskier than 96% of active trials completed
• Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM) NCT03691727 · started 2019 · scored riskier than 97% of active trials completed
• Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage NCT01893190 · started 2013 · scored riskier than 92% of active trials completed
• Clazosentan in Aneurysmal Subarachnoid Hemorrhage NCT00940095 · started 2009 · scored riskier than 97% of active trials terminated
• Evaluating Neuroprotection in Aneurysm Coiling Therapy NCT00728182 · started 2008 · scored riskier than 97% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.